Long-term treatment with the NO-donor molsidomine reduces circulating ICAM-1 levels in patients with stable angina

Hove, C. Van; Carreer-Bruhwyler, Fabienne; Géczy, Joseph; Herman, Arnold G.

doi:10.1016/j.atherosclerosis.2004.12.018

Cited by 19 publications

(14 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When compared with placebo, it reduced the incidence of anginal attacks, the use of sublingual nitrates, and increased exercise capacity in patients with stable angina [33,34]. Higher doses provided better protection from angina, although hypotension was a side effect [35].…”

Section: Molsidominementioning

confidence: 98%

Conventional and Novel Drug Therapeutics to Relief Myocardial Ischemia

Dvir

Battler

2010

Cardiovasc Drugs Ther

View full text Add to dashboard Cite

Effective management of stable angina usually includes drug therapy. There are several agents that are considered vasculoprotective such as aspirin, angiotensin converting enzyme inhibitors and statins. Conventional anti ischemic therapy includes nitrates, beta-blockers and calcium-channel blockers. In recent years, several other drugs with novel anti ischemic mechanisms have become available including ranolazine, ivabradine, nicorandil and many others. This article reviews drugs that alleviate the symptoms of chronic angina with emphasis on several novel pharmacological agents.

show abstract

Section: Molsidominementioning

confidence: 98%

Conventional and Novel Drug Therapeutics to Relief Myocardial Ischemia

Dvir

Battler

2010

Cardiovasc Drugs Ther

View full text Add to dashboard Cite

show abstract

“…In a randomized trial of 172 patients with stable angina, molsidomine reduced the level of soluble ICAM-1 (which is a marker for the severity of atherosclerosis) [89]. However, molsidomine was not associated with improved endothelial function in patients with significant coronary artery disease undergoing percutaneous coronary intervention [90].…”

Section: Management Of Anginamentioning

confidence: 99%

Advancements in pharmacotherapy for angina

Jain

Elgendy

Al‐Ani

et al. 2017

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

Introduction Angina pectoris is the most prevalent symptomatic manifestation of ischemic heart disease, frequently leads to a poor quality of life, and is a major cause of medical resource consumption. Since the early descriptions of nitrite and nitrate in the 19th century, there has been considerable advancement in the pharmacologic management of angina. Areas covered Management of chronic angina is often challenging for clinicians. Despite introduction of several pharmacological agents in last few decades, a significant proportion of patients continue to experience symptoms (i.e., refractory angina) with subsequent disability. For the purpose of this review, we searched PubMed and Cochrane databases from inception to August 2016 for the most clinically relevant publications that guide current practice in angina therapy and its development. In this article, we briefly review the pathophysiology of angina and mechanism-based classification of current therapy. This is followed by evidence-based insight into the traditional and novel pharmacotherapeutic agents, highlighting their clinical usefulness. Expert opinion Considering the wide array of available therapies with different mechanism efficacy and limiting factors, a personalized approach is essential, particularly for patients with refractory angina. Ongoing research with novel pharmacologic modalities is likely to provide new options for management of angina.

show abstract

“…In 172 patients with stable angina, molsidomine was associated with a reduction in the pro-inflammatory marker (soluble ICAM-1) after 4 weeks and 12 months of treatment. This medication was associated with a reduction in angina attacks and nitrate use [36]. Both higher (i.e., 16 mg daily) and lower doses (i.e., 8 mg daily) were demonstrated to improve angina, however, hypotension was a noticeable side effect from the higher dose [37].…”

Section: Traditional Pharmacological Therapies For Anginamentioning

confidence: 99%

Experimental and early investigational drugs for angina pectoris

Elgendy

Winchester

Pepine

2016

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

Introduction Ischemic heart disease (IHD) is a major cause of death and disability among Western countries and angina pectoris is the most prevalent symptomatic manifestation. Strategies to improve management of chronic stable angina are a priority. Areas covered A comprehensive review was conducted using the Medline and Cochrane databases as well as the clinical trial databases in the United States and Europe. Traditional therapies for angina will be discussed. This review particularly emphasizes investigational therapies for angina (including pharmacological agents, cell and gene based therapies, and herbal medications). Expert commentary There has been renewed interest in older anti-angina agents (e.g., perhexiline, amiodarone, and phosphodiestrase-5 inhibitors). Other anti-inflammatory agents (e.g., allopurinol and febuxostat) are currently undergoing evaluation for angina therapy. Therapeutic angiogenesis continues to face some challenges. Future trials should evaluate the optimum patient population that would benefit from this form of therapy.

show abstract

Long-term treatment with the NO-donor molsidomine reduces circulating ICAM-1 levels in patients with stable angina

Cited by 19 publications

References 40 publications

Conventional and Novel Drug Therapeutics to Relief Myocardial Ischemia

Conventional and Novel Drug Therapeutics to Relief Myocardial Ischemia

Advancements in pharmacotherapy for angina

Experimental and early investigational drugs for angina pectoris

Contact Info

Product

Resources

About